Furthermore, the immunohistochemical staining of tumour sections with an antibody that recognized the autophosphorylated Ser1003 of MRCKα as a biomarker of activity status revealed that BDP9066 was effective at reducing kinase activity. This evidence concerns the gene CDC42BPA and neoplasm.